Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Drug Resistance, Neoplasm"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 33715
Tytuł:
Disrupting cellular memory to overcome drug resistance.
Autorzy:
Harmange G; Cellular and Molecular Biology Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Hueros RAR; Department of Biochemistry and Molecular Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Schaff DL; Department of Bioengineering, School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia, PA, USA.
Emert B; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, 91125, USA.
Saint-Antoine M; Department of Electrical and Computer Engineering, University of Delaware, Newark, DE, 19716, USA.
Kim LC; Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Niu Z; Department of Chemistry, College of the Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.; Department of Physics, College of the Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.
Nellore S; Department of Biology, College of the Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.; The Wharton School, University of Pennsylvania, Philadelphia, PA, USA.
Fane ME; Cancer Signaling and Microenvironment Research Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Alicea GM; Department of Biochemistry and Molecular Biology, Johns Hopkins School of Public Health, Baltimore, MD, USA.
Weeraratna AT; Department of Biochemistry and Molecular Biology, Johns Hopkins School of Public Health, Baltimore, MD, USA.; Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Simon MC; Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Singh A; Department of Electrical and Computer Engineering, University of Delaware, Newark, DE, 19716, USA.
Shaffer SM; Department of Bioengineering, School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia, PA, USA. .; Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. .
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2023 Nov 06; Vol. 14 (1), pp. 7130. Date of Electronic Publication: 2023 Nov 06.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Phosphatidylinositol 3-Kinases*
Drug Resistance, Neoplasm*
Cell Differentiation/genetics ; Transforming Growth Factor beta
Czasopismo naukowe
Szczegóły
Tytuł:
Loss of LRP1B expression drives acquired chemo and radio-resistance in HPV-positive head and neck cancer.
Autorzy:
Shaikh MH; Department of Otolaryngology-Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada.
Dawson A; Department of Otolaryngology-Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada; Department of Pathology and Laboratory Medicine, University of Western Ontario, London, Ontario, Canada.
Prokopec SD; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Barrett JW; Department of Otolaryngology-Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada; Department of Oncology, University of Western Ontario, London, Ontario, Canada.
Y F Zeng P; Department of Otolaryngology-Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada.
Khan MI; Department of Otolaryngology-Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada.
Ryan SEB; Department of Otolaryngology-Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada; Department of Pathology and Laboratory Medicine, University of Western Ontario, London, Ontario, Canada.
Cecchini M; Department of Pathology and Laboratory Medicine, University of Western Ontario, London, Ontario, Canada.
Palma DA; Department of Otolaryngology-Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada; Department of Oncology, University of Western Ontario, London, Ontario, Canada.
Mymryk JS; Department of Otolaryngology-Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada; Department of Oncology, University of Western Ontario, London, Ontario, Canada; Department of Microbiology & Immunology, University of Western Ontario, London, Ontario, Canada.
Boutros PC; Department of Human Genetics, University of California, Los Angeles, CA, USA; Department of Urology, University of California, Los Angeles, CA, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA, USA; Institute for Precision Health, University of California, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Centre, University of California, Los Angeles, CA, USA.
Nichols AC; Department of Otolaryngology-Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada; Department of Oncology, University of Western Ontario, London, Ontario, Canada. Electronic address: .
Pokaż więcej
Źródło:
Oral oncology [Oral Oncol] 2023 Nov; Vol. 146, pp. 106580. Date of Electronic Publication: 2023 Sep 30.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Squamous Cell*/pathology
Head and Neck Neoplasms*/drug therapy
Head and Neck Neoplasms*/genetics
Head and Neck Neoplasms*/radiotherapy
Oropharyngeal Neoplasms*
Papillomavirus Infections*/complications
Papillomavirus Infections*/genetics
Papillomavirus Infections*/pathology
Drug Resistance, Neoplasm*
Radiation Tolerance*
Humans ; Cisplatin/pharmacology ; Cisplatin/therapeutic use ; Neoplasm Recurrence, Local ; Receptors, LDL/therapeutic use ; Squamous Cell Carcinoma of Head and Neck/genetics ; Squamous Cell Carcinoma of Head and Neck/radiotherapy
Czasopismo naukowe
Szczegóły
Tytuł:
Vav1-dependent Rac1 activation mediates hypoxia-induced gemcitabine resistance in pancreatic ductal adenocarcinoma cells through upregulation of HIF-1α expression.
Autorzy:
Zhu C; Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.; Department of General Surgery, Affiliated Hospital of Jiangnan University, Wuxi, China.
Hu H; Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Jiangnan University, Wuxi, China.
Ma Y; Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xiong S; Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Jiangnan University, Wuxi, China.
Zhu D; Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
Pokaż więcej
Źródło:
Cell biology international [Cell Biol Int] 2023 Nov; Vol. 47 (11), pp. 1835-1842. Date of Electronic Publication: 2023 Aug 06.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Pancreatic Ductal*/drug therapy
Carcinoma, Pancreatic Ductal*/metabolism
Carcinoma, Pancreatic Ductal*/pathology
Gemcitabine*
Pancreatic Neoplasms*/metabolism
Drug Resistance, Neoplasm*
Humans ; Cell Line, Tumor ; Hypoxia ; Up-Regulation
SCR Disease Name:
Pancreatic Carcinoma
Czasopismo naukowe
Szczegóły
Tytuł:
CAB39 promotes cisplatin resistance in bladder cancer via the LKB1-AMPK-LC3 pathway.
Autorzy:
Gao D; Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical Center, Lanzhou, Gansu, 730030, China.
Wang R; Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical Center, Lanzhou, Gansu, 730030, China.
Gong Y; Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical Center, Lanzhou, Gansu, 730030, China.
Yu X; Ministry of Education Key Laboratory of Cell Activities and Stress Adaptations, School of Life Sciences, Lanzhou University, Lanzhou, 730000, China.
Niu Q; Department of Pathology, Lanzhou University Second Hospital, Lanzhou, China.
Yang E; Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical Center, Lanzhou, Gansu, 730030, China.
Fan G; Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical Center, Lanzhou, Gansu, 730030, China.
Ma J; Department of Urology, Lanzhou University Second Hospital, Lanzhou, China.
Chen C; Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical Center, Lanzhou, Gansu, 730030, China.
Tao Y; Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical Center, Lanzhou, Gansu, 730030, China.
Lu J; Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical Center, Lanzhou, Gansu, 730030, China.
Wang Z; Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical Center, Lanzhou, Gansu, 730030, China. Electronic address: .
Pokaż więcej
Źródło:
Free radical biology & medicine [Free Radic Biol Med] 2023 Nov 01; Vol. 208, pp. 587-601. Date of Electronic Publication: 2023 Sep 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cisplatin*/pharmacology
Cisplatin*/therapeutic use
Drug Resistance, Neoplasm*/genetics
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/genetics
Urinary Bladder Neoplasms*/pathology
Humans ; AMP-Activated Protein Kinases/genetics ; AMP-Activated Protein Kinases/metabolism ; Apoptosis ; Autophagy ; Cell Line, Tumor ; Chloroquine/pharmacology ; Proteomics ; Reactive Oxygen Species/metabolism
Czasopismo naukowe
Szczegóły
Tytuł:
Canagliflozin reduces chemoresistance in hepatocellular carcinoma through PKM2-c-Myc complex-mediated glutamine starvation.
Autorzy:
Zeng Y; Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Jiang H; Department of Radiation Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China; Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Zhang X; Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xu J; Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Wu X; Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xu Q; Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Cai W; Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Ying H; Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Zhou R; Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Ding Y; Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Ying K; Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Song X; Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Chen Z; Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Zeng L; Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Zhao L; Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. Electronic address: .
Yu F; Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. Electronic address: .
Pokaż więcej
Źródło:
Free radical biology & medicine [Free Radic Biol Med] 2023 Nov 01; Vol. 208, pp. 571-586. Date of Electronic Publication: 2023 Sep 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/genetics
Carcinoma, Hepatocellular*/metabolism
Drug Resistance, Neoplasm*/genetics
Liver Neoplasms*/drug therapy
Liver Neoplasms*/genetics
Liver Neoplasms*/metabolism
Humans ; Canagliflozin/pharmacology ; Canagliflozin/therapeutic use ; Cell Line, Tumor ; Cell Proliferation ; Glutamine/metabolism ; Glycolysis ; Proto-Oncogene Proteins c-myc/drug effects
Czasopismo naukowe
Szczegóły
Tytuł:
Perturbations in 3D genome organization can promote acquired drug resistance.
Autorzy:
Manjón AG; Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands; Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands.
Manzo SG; Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands; Division of Gene Regulation, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands; Department of Biosciences, Università degli Studi di Milano, Via Celoria 26, 20133 Milan, Italy.
Prekovic S; Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands; Center for Molecular Medicine, University Medical Center Utrecht and Utrecht University, 3584 CX Utrecht, the Netherlands.
Potgeter L; Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands; Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands.
van Schaik T; Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands; Division of Gene Regulation, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands.
Liu NQ; Division of Gene Regulation, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands; Department of Hematology, Erasmus Medical Center (MC) Cancer Institute, Rotterdam, the Netherlands.
Flach K; Division of Gene Regulation, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands.
Peric-Hupkes D; Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands; Division of Gene Regulation, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands.
Joosten S; Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands.
Teunissen H; Division of Gene Regulation, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands.
Friskes A; Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands; Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands.
Ilic M; Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands; Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands.
Hintzen D; Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands; Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands.
Franceschini-Santos VH; Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands; Division of Gene Regulation, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands.
Zwart W; Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands.
de Wit E; Division of Gene Regulation, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands.
van Steensel B; Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands; Division of Gene Regulation, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands. Electronic address: .
Medema RH; Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands; Division of Cell Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands. Electronic address: .
Pokaż więcej
Źródło:
Cell reports [Cell Rep] 2023 Oct 31; Vol. 42 (10), pp. 113124. Date of Electronic Publication: 2023 Sep 20.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Resistance, Neoplasm*/genetics
Neoplasms*/genetics
Humans ; Paclitaxel/pharmacology ; Drug Resistance, Multiple/genetics ; DNA Methylation/genetics ; Cell Line, Tumor
Czasopismo naukowe
Szczegóły
Tytuł:
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.
Autorzy:
Mohanty A; Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA 91010, USA.
Nam A; Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA 91010, USA.
Srivastava S; Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA 91010, USA.
Jones J; Proteome Exploration Laboratory, California Institute of Technology, Pasadena, CA 91125, USA.
Lomenick B; Proteome Exploration Laboratory, California Institute of Technology, Pasadena, CA 91125, USA.
Singhal SS; Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA 91010, USA.
Guo L; Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA 91010, USA.
Cho H; Integrative Genomics Core, Beckman Research Institute, City of Hope, Monrovia, CA 91016, USA.
Li A; Department of Pathology, City of Hope National Medical Center, Duarte, CA 91010,USA.
Behal A; Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA 91010, USA.
Mirzapoiazova T; Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA 91010, USA.
Massarelli E; Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA 91010, USA.
Koczywas M; Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA 91010, USA.
Arvanitis LD; Department of Pathology, City of Hope National Medical Center, Duarte, CA 91010,USA.
Walser T; Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA 91010, USA.
Villaflor V; Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA 91010, USA.
Hamilton S; Department of Pathology, City of Hope National Medical Center, Duarte, CA 91010,USA.
Mambetsariev I; Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA 91010, USA.
Sattler M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Nasser MW; Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Jain M; Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Batra SK; Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Soldi R; Applied Cancer Research and Drug Discovery Division, Translational Genomics Research Institute (TGen) of City of Hope, Phoenix, AZ 850043, USA.
Sharma S; Applied Cancer Research and Drug Discovery Division, Translational Genomics Research Institute (TGen) of City of Hope, Phoenix, AZ 850043, USA.
Fakih M; Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA 91010, USA.
Mohanty SK; Department of Chemical Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur, West Bengal 741246, India.
Mainan A; Department of Chemical Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur, West Bengal 741246, India.
Wu X; Integrative Genomics Core, Beckman Research Institute, City of Hope, Monrovia, CA 91016, USA.
Chen Y; W. M. Keck Laboratory for Structural Biology, University of Maryland Institute for Bioscience and Biotechnology Research, Rockville, MD 20850, USA.
He Y; W. M. Keck Laboratory for Structural Biology, University of Maryland Institute for Bioscience and Biotechnology Research, Rockville, MD 20850, USA.
Chou TF; Proteome Exploration Laboratory, California Institute of Technology, Pasadena, CA 91125, USA.
Roy S; Department of Chemical Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur, West Bengal 741246, India.
Orban J; W. M. Keck Laboratory for Structural Biology, University of Maryland Institute for Bioscience and Biotechnology Research, Rockville, MD 20850, USA.; Department of Chemistry and Biochemistry, University of Maryland, College Park, MD 20742, USA.
Kulkarni P; Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA 91010, USA.
Salgia R; Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA 91010, USA.
Pokaż więcej
Źródło:
Science advances [Sci Adv] 2023 Oct 13; Vol. 9 (41), pp. eade3816. Date of Electronic Publication: 2023 Oct 13.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Drug Resistance, Neoplasm*/genetics
Humans ; Antiviral Agents ; beta Catenin/genetics ; Mutation ; Proto-Oncogene Proteins p21(ras)/genetics
Czasopismo naukowe
Szczegóły
Tytuł:
Fatty acid binding protein 5 regulates docetaxel sensitivity in taxane-resistant prostate cancer cells.
Autorzy:
Hillowe A; Department of Anesthesiology, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, United States of America.
Gordon C; Department of Anesthesiology, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, United States of America.
Wang L; Department of Anesthesiology, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, United States of America.
Rizzo RC; Department of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, New York, United States of America.
Trotman LC; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, United States of America.
Ojima I; Department of Chemistry, Stony Brook University, Stony Brook, New York, United States of America.; Institute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, New York, United States of America.
Bialkowska A; Institute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, New York, United States of America.; Department of Medicine, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, United States of America.
Kaczocha M; Department of Anesthesiology, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, United States of America.; Institute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, New York, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Oct 05; Vol. 18 (10), pp. e0292483. Date of Electronic Publication: 2023 Oct 05 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Drug Resistance, Neoplasm*/genetics
Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms*/genetics
Prostatic Neoplasms*/metabolism
Male ; Humans ; Docetaxel/pharmacology ; Cell Line, Tumor ; Taxoids/pharmacology ; ATP Binding Cassette Transporter, Subfamily B/metabolism ; Fatty Acid-Binding Proteins/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Inhibition of Eukaryotic Initiating Factor eIF4E Overcomes Abemaciclib Resistance in Gastric Cancer.
Autorzy:
Zha HL; Department of Gastroenterology, Renmin Hospital, Hubei University of Medicine, Shiyan, 442000, China.
Chen W; Department of Critical Care Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, China.
Shi W; Department of Gastroenterology, Renmin Hospital, Hubei University of Medicine, Shiyan, 442000, China. .
Liao YY; Department of Gastroenterology, Renmin Hospital, Hubei University of Medicine, Shiyan, 442000, China. .
Pokaż więcej
Źródło:
Current medical science [Curr Med Sci] 2023 Oct; Vol. 43 (5), pp. 927-934. Date of Electronic Publication: 2023 Sep 27.
Typ publikacji:
Journal Article
MeSH Terms:
Ribavirin*
Stomach Neoplasms*/drug therapy
Stomach Neoplasms*/genetics
Drug Resistance, Neoplasm*
Aminopyridines*/therapeutic use
Animals ; Humans ; Mice ; Cell Line, Tumor ; Eukaryotic Initiation Factor-4E/genetics ; Eukaryotic Initiation Factor-4E/metabolism
Czasopismo naukowe
Szczegóły
Tytuł:
RNA methylation, homologous recombination repair and therapeutic resistance.
Autorzy:
Bai Y; Department of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang, China; Department of Nephrology, Shengjing Hospital of China Medical University, Shenyang, China.
Zhao H; Department of Ion Channel Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
Liu H; Department of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
Wang W; Department of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang, China. Electronic address: .
Dong H; Department of Anatomy, College of Basic Medical Science, China Medical University, Shenyang, China. Electronic address: .
Zhao C; Department of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang, China. Electronic address: .
Pokaż więcej
Źródło:
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2023 Oct; Vol. 166, pp. 115409. Date of Electronic Publication: 2023 Sep 04.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Recombinational DNA Repair*
Drug Resistance, Neoplasm*/genetics
Humans ; Methylation ; Histones/genetics ; RNA
Czasopismo naukowe
Szczegóły
Tytuł:
Targeting DHODH reveals therapeutic opportunities in ATRA-resistant acute promyelocytic leukemia.
Autorzy:
Yang T; Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China.
Shi X; Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China.
Li S; Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China.
Zhao Z; Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China.
Wang J; Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China.
Yu P; Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China.
Li H; Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China; Innovation Center for AI and Drug Discovery, East China Normal University, Shanghai 200062, China; Lingang Laboratory, Shanghai 200031, China. Electronic address: .
Wang R; Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China. Electronic address: .
Chen Z; Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science & Technology, Shanghai 200237, China. Electronic address: .
Pokaż więcej
Źródło:
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2023 Oct; Vol. 166, pp. 115314. Date of Electronic Publication: 2023 Aug 12.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Dihydroorotate Dehydrogenase*/antagonists & inhibitors
Dihydroorotate Dehydrogenase*/genetics
Dihydroorotate Dehydrogenase*/metabolism
Drug Resistance, Neoplasm*
Leukemia, Promyelocytic, Acute*/drug therapy
Leukemia, Promyelocytic, Acute*/genetics
Leukemia, Promyelocytic, Acute*/metabolism
Tretinoin*/pharmacology
Tretinoin*/therapeutic use
Animals ; Mice ; Cell Differentiation
Czasopismo naukowe
Szczegóły
Tytuł:
Hsa-miR-503-5p regulates CTDSPL to accelerate cisplatin resistance and angiogenesis of lung adenocarcinoma cells.
Autorzy:
Han J; Department of Thoracic Surgery, First People's Hospital of Jiande, Jiande, China.
Wang Y; Department of Medical Imaging, First People's Hospital of Jiande, Jiande, China.
Pokaż więcej
Źródło:
Chemical biology & drug design [Chem Biol Drug Des] 2023 Oct; Vol. 102 (4), pp. 749-762. Date of Electronic Publication: 2023 Jun 21.
Typ publikacji:
Journal Article
MeSH Terms:
Adenocarcinoma of Lung*/drug therapy
Adenocarcinoma of Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
MicroRNAs*/genetics
Drug Resistance, Neoplasm*/genetics
Humans ; Cell Line, Tumor ; Cell Proliferation ; Cisplatin/pharmacology ; Vascular Endothelial Growth Factor A
Czasopismo naukowe
Szczegóły
Tytuł:
USP8 promotes gemcitabine resistance of pancreatic cancer via deubiquitinating and stabilizing Nrf2.
Autorzy:
Cui J; Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Guo Y; Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Yin T; Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Gou S; Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Xiong J; Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Liang X; Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Lu C; Department of Thyroid and Breast Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address: .
Peng T; Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address: .
Pokaż więcej
Źródło:
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2023 Oct; Vol. 166, pp. 115359. Date of Electronic Publication: 2023 Aug 28.
Typ publikacji:
Journal Article
MeSH Terms:
Gemcitabine*
Pancreatic Neoplasms*/drug therapy
Drug Resistance, Neoplasm*
Humans ; Endopeptidases ; Endosomal Sorting Complexes Required for Transport ; NF-E2-Related Factor 2 ; Signal Transduction ; Ubiquitin Thiolesterase/genetics
SCR Disease Name:
Pancreatic Carcinoma
Czasopismo naukowe
Szczegóły
Tytuł:
RXR agonist, Bexarotene, effectively reduces drug resistance via regulation of RFX1 in embryonic carcinoma cells.
Autorzy:
Issac J; Cancer Research Program-12, Rajiv Gandhi Centre for Biotechnology (DBT-RGCB), Thycaud. P.O. Thiruvananthapuram-14, Kerala, India.
Raveendran PS; Cancer Research Program-12, Rajiv Gandhi Centre for Biotechnology (DBT-RGCB), Thycaud. P.O. Thiruvananthapuram-14, Kerala, India; Manipal Academy of Higher Education, Tiger Circle Road, Madhav Nagar, Manipal, Karnataka 576104, India.
Kunnummal M; Cancer Research Program-12, Rajiv Gandhi Centre for Biotechnology (DBT-RGCB), Thycaud. P.O. Thiruvananthapuram-14, Kerala, India; Manipal Academy of Higher Education, Tiger Circle Road, Madhav Nagar, Manipal, Karnataka 576104, India.
Angelin M; Cancer Research Program-12, Rajiv Gandhi Centre for Biotechnology (DBT-RGCB), Thycaud. P.O. Thiruvananthapuram-14, Kerala, India.
Ravindran S; Cancer Research Program-12, Rajiv Gandhi Centre for Biotechnology (DBT-RGCB), Thycaud. P.O. Thiruvananthapuram-14, Kerala, India.
Basu B; Neuro Stem Cell Biology Laboratory, Neurobiology Division, Rajiv Gandhi Centre for Biotechnology (DBT-RGCB), Thiruvananthapuram, Kerala 695 014, India; Regional Centre for Biotechnology (DBT-RCB), Faridabad, Haryana 121001, India.
Das AV; Cancer Research Program-12, Rajiv Gandhi Centre for Biotechnology (DBT-RGCB), Thycaud. P.O. Thiruvananthapuram-14, Kerala, India; Manipal Academy of Higher Education, Tiger Circle Road, Madhav Nagar, Manipal, Karnataka 576104, India. Electronic address: .
Pokaż więcej
Źródło:
Biochimica et biophysica acta. Molecular cell research [Biochim Biophys Acta Mol Cell Res] 2023 Oct; Vol. 1870 (7), pp. 119510. Date of Electronic Publication: 2023 Jun 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma*
Regulatory Factor X1*/drug effects
Regulatory Factor X1*/metabolism
Drug Resistance, Neoplasm*/drug effects
Humans ; Bexarotene/pharmacology ; Cisplatin/pharmacology ; DNA-Binding Proteins/genetics ; DNA-Binding Proteins/metabolism ; NF-E2-Related Factor 2/genetics ; Regulatory Factor X Transcription Factors ; Drug Resistance, Multiple/drug effects
Czasopismo naukowe
Szczegóły
Tytuł:
Tspan15-ADAM10 signalling enhances cancer stem cell-like properties and induces chemoresistance via Notch1 activation in ICC.
Autorzy:
Yoshizumi A; Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Kuboki S; Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takayashiki T; Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takano S; Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takayanagi R; Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Sonoda I; Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Ohtsuka M; Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Pokaż więcej
Źródło:
Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2023 Oct; Vol. 43 (10), pp. 2275-2291. Date of Electronic Publication: 2023 Aug 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Drug Resistance, Neoplasm*/genetics
Neoplasms*
Humans ; ADAM10 Protein/genetics ; ADAM10 Protein/metabolism ; Signal Transduction ; Neoplastic Stem Cells/pathology ; Receptor, Notch1/genetics ; Receptor, Notch1/metabolism ; Cell Line, Tumor ; Membrane Proteins/genetics ; Membrane Proteins/metabolism ; Amyloid Precursor Protein Secretases/genetics ; Amyloid Precursor Protein Secretases/metabolism
Czasopismo naukowe
Szczegóły
Tytuł:
TMED2 Induces Cisplatin Resistance in Breast Cancer via Targeting the KEAP1-Nrf2 Pathway.
Autorzy:
Liang C; College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan, 430070, China.
Zhang HY; School of Stomatology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Wang YQ; College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan, 430070, China.
Yang LA; College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan, 430070, China.
Du YS; College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan, 430070, China.
Luo Y; College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan, 430070, China.
Zhang TC; College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan, 430070, China.
Xu Y; College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan, 430070, China. .
Pokaż więcej
Źródło:
Current medical science [Curr Med Sci] 2023 Oct; Vol. 43 (5), pp. 1023-1032. Date of Electronic Publication: 2023 Aug 24.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Cisplatin*/pharmacology
Cisplatin*/therapeutic use
Drug Resistance, Neoplasm*/genetics
Female ; Humans ; Kelch-Like ECH-Associated Protein 1/genetics ; Membrane Proteins/metabolism ; NF-E2-Related Factor 2/genetics ; NF-E2-Related Factor 2/metabolism ; Vesicular Transport Proteins/metabolism
Czasopismo naukowe
Szczegóły
Tytuł:
TCFL5 knockdown sensitizes DLBCL to doxorubicin treatment via regulation of GPX4.
Autorzy:
Lu X; Graduate School, Nanjing Medical University, Nanjing 210000, China.
Zhang Q; Department of Hematology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian 223300, China.
Xie Y; Graduate School, Nanjing Medical University, Nanjing 210000, China. Electronic address: .
Pokaż więcej
Źródło:
Cellular signalling [Cell Signal] 2023 Oct; Vol. 110, pp. 110831. Date of Electronic Publication: 2023 Jul 27.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Resistance, Neoplasm*/genetics
Lymphoma, Large B-Cell, Diffuse*/metabolism
Phospholipid Hydroperoxide Glutathione Peroxidase*/metabolism
Basic Helix-Loop-Helix Transcription Factors*/genetics
Animals ; Mice ; Cell Line, Tumor ; Cyclophosphamide/pharmacology ; Doxorubicin/pharmacology ; Doxorubicin/therapeutic use ; Vincristine/pharmacology ; Vincristine/therapeutic use ; Humans
Czasopismo naukowe
Szczegóły
Tytuł:
Wnt/β-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells.
Autorzy:
Kim Y; Department of Internal Medicine, Division of Gastroenterology, Gangnam Severance Hospital, Yonsei University College of Medicine, 20, Eonju-ro 63-gil, Gangnam-gu, Seoul, 06229, Korea.
Bae YJ; Department of Internal Medicine, Division of Gastroenterology, Gangnam Severance Hospital, Yonsei University College of Medicine, 20, Eonju-ro 63-gil, Gangnam-gu, Seoul, 06229, Korea.
Kim JH; Department of Internal Medicine, Division of Gastroenterology, Gangnam Severance Hospital, Yonsei University College of Medicine, 20, Eonju-ro 63-gil, Gangnam-gu, Seoul, 06229, Korea. .
Kim H; Department of Pathology, Yonsei University College of Medicine, Seoul, 03722, Korea.
Shin SJ; Department of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, 06229, Korea.
Jung DH; Department of Internal Medicine, Division of Gastroenterology, Yonsei University College of Medicine, Seoul, 03722, Korea.
Park H; Department of Internal Medicine, Division of Gastroenterology, Gangnam Severance Hospital, Yonsei University College of Medicine, 20, Eonju-ro 63-gil, Gangnam-gu, Seoul, 06229, Korea.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Sep 29; Vol. 23 (1), pp. 922. Date of Electronic Publication: 2023 Sep 29.
Typ publikacji:
Journal Article
MeSH Terms:
Stomach Neoplasms*/genetics
Wnt Signaling Pathway*
Drug Resistance, Neoplasm*
Humans ; beta Catenin/metabolism ; Cell Line, Tumor ; Cell Movement ; Epithelial-Mesenchymal Transition ; Trastuzumab/pharmacology ; Trastuzumab/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The endocytic receptor protein LRP-1 modulate P-glycoprotein mediated drug resistance in MCF-7 cells.
Autorzy:
Henry A; UMR-CNRS 7369 Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), UFR SEN, URCA, Reims cedex, France.
Mauperin M; UMR-CNRS 7369 Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), UFR SEN, URCA, Reims cedex, France.
Devy J; UMR-CNRS 7369 Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), UFR SEN, URCA, Reims cedex, France.
Dedieu S; UMR-CNRS 7369 Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), UFR SEN, URCA, Reims cedex, France.
Chazee L; UMR-CNRS 7369 Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), UFR SEN, URCA, Reims cedex, France.
Hachet C; UMR-CNRS 7369 Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), UFR SEN, URCA, Reims cedex, France.
Terryn C; Technical Platform for Cellular and Tissue Imaging (PICT), UFR Pharmacie, URCA, Reims, France.
Duca L; UMR-CNRS 7369 Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), UFR SEN, URCA, Reims cedex, France.
Martiny L; UMR-CNRS 7369 Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), UFR SEN, URCA, Reims cedex, France.
Devarenne-Charpentier E; UMR-CNRS 7369 Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), UFR SEN, URCA, Reims cedex, France.
Btaouri HE; UMR-CNRS 7369 Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), UFR SEN, URCA, Reims cedex, France.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Sep 28; Vol. 18 (9), pp. e0285834. Date of Electronic Publication: 2023 Sep 28 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents*/pharmacology
ATP Binding Cassette Transporter, Subfamily B, Member 1*/metabolism
Drug Resistance, Neoplasm*
Low Density Lipoprotein Receptor-Related Protein-1*/metabolism
Humans ; Carrier Proteins/pharmacology ; Doxorubicin/pharmacology ; MCF-7 Cells
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Drug metabolism-related gene ABCA1 augments temozolomide chemoresistance and immune infiltration abundance of M2 macrophages in glioma.
Autorzy:
Yan Y; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Liu Y; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Liang Q; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Xu Z; Department of Pathology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. .; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. .
Pokaż więcej
Źródło:
European journal of medical research [Eur J Med Res] 2023 Sep 25; Vol. 28 (1), pp. 373. Date of Electronic Publication: 2023 Sep 25.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Resistance, Neoplasm*/genetics
Glioma*/drug therapy
Glioma*/genetics
Humans ; Temozolomide/pharmacology ; ATP Binding Cassette Transporter 1/genetics ; Molecular Docking Simulation ; Macrophages
Czasopismo naukowe
Szczegóły
Wyświetlanie 1-20 z 33715

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies